DNL.L Regulatory News (DNL)

Diurnal Group PLC

("Diurnal" or the "Company")

Block Admission Application

Diurnal Group PLC (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that an application has been made to the London Stock Exchange for a block admission of 1,171,533 ordinary shares of 5 pence each ("Ordinary Shares") to be admitted to trading on AIM ("Block Admission").

The Block Admission relates to Ordinary Shares that will be issued from time to time in connection with the Company's share plans, including satisfying outstanding options already issued under the Diurnal Share Option Scheme 2015, options issued on the same terms as those issued under the Company's long term incentive plan or share options issued in September 2015. All Ordinary Shares issued pursuant to the Block Admission above will rank pari passu with the existing Ordinary Shares.

It is expected that the Block Admission will become effective on or around 13 October 2022. The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.

For further information, please contact:

Diurnal Group PLC 020 3727 1000

Richard Bungay, Interim Chief Executive Officer

FTI Consulting (Media and Investor Relations) 020 3727 1000

Simon Conway

Victoria Foster Mitchell

Alex Davis

Panmure Gordon (Nomad and Broker) 020 7886 2500

Freddy Crossley

Emma Earl

Rupert Dearden

About Diurnal

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information please visit: www.diurnal.co.uk